You are here

Inflammatory bowel disease is presenting sooner after immigration in more recent US immigrants from Cuba.

Inflammatory bowel disease is presenting sooner after immigration in more recent US immigrants from Cuba. Aliment Pharmacol Ther. 2017 May 19;: Authors: Damas OM, Avalos DJ, Palacio AM, Gomez L, Quintero MA, Deshpande AR, Sussman DA, McCauley JL, Lopez J, Schwartz SJ, Abreu MT Abstract BACKGROUND: Despite a rising incidence of inflammatory bowel disease (IBD) in Hispanics in the United States, there are no studies examining the relationship between immigrant generation and IBD onset among Hispanics. AIMS: To determine whether age of IBD diagnosis, time from immigration to IBD diagnosis…

Read More

Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease.

Related Articles Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease. Aliment Pharmacol Ther. 2017 May 08;: Authors: van Haaften WT, Mortensen JH, Karsdal MA, Bay-Jensen AC, Dijkstra G, Olinga P Abstract BACKGROUND: Misbalances in extracellular matrix turnover are key factors in the development of stricturing (Montreal B2) and penetrating (Montreal B3) Crohn’s disease. AIM: To determine whether serological markers for collagen formation and degradation could serve as biomarkers for complications of Crohn’s disease. METHODS: Serum biomarkers for type I, III, V…

Read More

Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors.

Related Articles Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther. 2017 May 08;: Authors: Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM Abstract BACKGROUND: Discriminative drug level thresholds for disease activity endpoints in patients with Crohn’s disease. have been consistently demonstrated with infliximab, but not adalimumab. AIMS: To identify threshold concentrations for infliximab and adalimumab in Crohn’s disease according to different disease endpoints,…

Read More

The benefit of combination therapy depends on disease phenotype and duration in Crohn’s disease.

The benefit of combination therapy depends on disease phenotype and duration in Crohn’s disease. Aliment Pharmacol Ther. 2017 May 03;: Authors: Ananthakrishnan AN, Sakuraba A, Barnes EL, Pekow J, Raffals L, Long MD, Sandler RS Abstract BACKGROUND: The impact of combination therapy on disease-related morbidity in patients with established Crohn’s disease (CD) or ulcerative colitis (UC) remains to be well-defined. AIM: To examine the effect of combination therapy on disease outcomes in CD and UC. METHODS: Using a multicenter prospective cohort, we classified CD and UC patients as being on…

Read More

Systematic review: interventions for abdominal pain management in inflammatory bowel disease.

Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 May 04;: Authors: Norton C, Czuber-Dochan W, Artom M, Sweeney L, Hart A Abstract BACKGROUND: Abdominal pain is frequently reported by people with inflammatory bowel disease (IBD), including in remission. Pain is an under-treated symptom. AIM: To systematically review evidence on interventions (excluding disease-modifying interventions) for abdominal pain management in IBD. METHODS: Databases (MEDLINE, EMBASE, PsycInfo, CINAHL, Scopus, Cochrane Library) were searched (February 2016). Two researchers independently screened references and extracted data. RESULTS: Fifteen papers…

Read More

A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease.

A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Apr 27;: Authors: Coughlan A, Wylde R, Lafferty L, Quinn S, Broderick A, Bourke B, Hussey S, DOCHAS Study Abstract BACKGROUND: The incidence of paediatric inflammatory bowel disease diagnosed before age 10 years is reportedly increasing, but national data are limited. AIM: To characterise the epidemiology, phenotype and clinical outcomes of children diagnosed with inflammatory bowel disease before age 10 years, and compare with data from children diagnosed aged 10-16 years. METHODS: A review of…

Read More
<< Go Back